A director at Tenet Healthcare Corp sold 2,178 shares at 197.470USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...
Moody's Ratings (Moody's) assigned Ba3 rating to Tenet Healthcare Corporation's ("Tenet") proposed offering of senior secured first lien notes due 2032 and B2 rating to the senior unsecured notes proposed offering due 2033. Tenet intends to use the net proceeds from this offering for general corpora...
Moody's Ratings (Moody's) affirmed the ratings of Tenet Healthcare Corporation ("Tenet") including the Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rating (PDR), Ba3 ratings of senior secured first and second lien notes and B2 rating of senior unsecured notes. At the same time, w...
Expecting a Test of All-Time Highs The market remains relentlessly strong, shrugging off the latest "bearish" headline regarding Moody's U.S. debt downgrade on Friday. This is exactly what we would expect to happen in a bull market, particularly during this "lockout rally," and helps confirm our bullish outlook. To recap, we have been short-term bullish since our 4/22/25 Compass -- when the SPX was testing 5100-5120 support -- but we upgraded our intermediate-term outlook to bullish as well, as...
SPX Testing Resistance as Rate Cut Cycle Begins The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 57...
Moody's Ratings (Moodys) assigned a Baa3 rating to Universal Health Services, Inc.'s ("UHS") proposed offering of senior secured notes of up to $1.0 billion. UHS will use proceeds from the new senior secured notes to partially pay down the outstanding balance on its existing senior secured term loan...
Upgrading Consumer Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow Our long-term outlook remains neutral on the S&P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023. In late-July (7/30/24 Compass) we discussed expectations for a 1- to 4-month pullback/consolidation period on the SPX and Nasdaq 100 (QQQ), and at this point it seems likely to last closer to four months, and potentially 4- to 6-months from our selected 7/17/2...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
A director at Universal Health Services Inc sold 850 shares at 212.110USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.